Replies to post #247309 on Biotech Values

[Mufaso]

VKTX- I agree VK-0214 is a significant overlooked Viking asset.

However I was expecting the results for the 1b trial in X-ALD more towards the end of the year (e.g. 4th q) rather than the next few months. I am thinking this because the 1b trial was still enrolling as of the 1st q cc which was 4-26. CEO Brian Lian in his prepared remarks then said:

The current phase 1b study is enrolling adult males and will run 28 days…With our VK0214 program, we continued enrolling our Phase 1b study in patients with adrenomyeloneuropathy and we anticipate reporting data from this study later in the year.